Adiposity and low-grade systemic inflammation modulate matrix metalloproteinase-9 levels in Greek children with sleep apnea

Pediatric Pulmonology

Volumn 45, Issue 7, 2010, Pages 693-699

  Kaditis, Athanasios G ^a   Alexopoulos, Emmanouel I ^a   Karathanasi, Anastasia ^a   Ntamagka, Georgia ^a   Oikonomidi, Smaragda ^a   Kiropoulos, Theodoros S ^a   Zintzaras, Elias ^a   Gourgoulianis, Konstantinos ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Child; Inflammation; Sleep apnea

Indexed keywords

C REACTIVE PROTEIN; GELATINASE B;

ARTICLE; BODY MASS; CHILD; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; GREECE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OBESITY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; SLEEP APNEA SYNDROME; SNORING;

ADIPOSITY; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; FEMALE; GREECE; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 9; POLYSOMNOGRAPHY; SEVERITY OF ILLNESS INDEX; SLEEP APNEA, OBSTRUCTIVE; SNORING;

EID: 77954433742     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21251     Document Type: Article

References (47)

1. Lavie L. Obstructive sleep apnoea syndrome - an oxidative stress disorder. Sleep Med Rev 2003;7:35-51.
2. Gozal D, Kheirandish-Gozal L. Cardiovascular morbidity in obstructive sleep apnea: oxidative stress, inflammation, and much more. Am J Respir Crit Care Med 2008;177:369-375.
3. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002; 165:934-939. (Pubitemid 34774660)
4. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol 2008;52:686-717.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
6. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-1818.
7. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-868.
8. Nomoto K, Oguchi S, Watanabe I, Kushiro T, Kanmatsuse K. Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1. J Cardiol 2003;42:201-206.
9. Shamsuzzaman AS, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V, Somers VK. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002;105:2462-2464.
10. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, Hirano T, Adachi M. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003;107:1129-1134.
11. Tazaki T, Minoguchi K, Yokoe T, Samson KT, Minoguchi H, Tanaka A,Watanabe Y, Adachi M. Increased levels and activity of matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004;170:1354-1359.
12. Ye J, Liu H, Li Y, Liu X, Zhu JM. Increased serum levels of Creactive protein and matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Chin Med J (Engl) 2007;120:1482-1486.
13. Tamaki S, Yamauchi M, Fukuoka A, Makinodan K, Koyama N, Tomoda K, Yoshikawa M, Kimura H. Production of inflammatory mediators by monocytes in patients with obstructive sleep apnea syndrome. Intern Med 2009;48:1255-1262.
14. Tauman R, Ivanenko A, O'Brien LM, Gozal D. Plasma C-reactive protein levels among children with sleep-disordered breathing. Pediatrics 2004;113:e564-e569.
15. Gozal D, Crabtree VM, Sans Capdevila O, Witcher LA, Kheirandish-Gozal L. C-reactive protein, obstructive sleep apnea, and cognitive dysfunction in school-aged children. Am J Respir Crit Care Med 2007;176:188-193. (Pubitemid 47057856)
16. Li AM, Chan MH, Yin J, So HK, Ng SK, Chan IH, Lam CW, Wing YK, Ng PC. C-reactive protein in children with obstructive sleep apnea and the effects of treatment. Pediatr Pulmonol 2008; 43:34-40.
17. Kaditis AG, Alexopoulos EI, Kalampouka E, Kostadima E, Germenis A, Zintzaras E, Gourgoulianis K. Morning levels of Creactive protein in children with obstructive sleep-disordered breathing. Am J Respir Crit Care Med 2005;171:282-286.
18. Apostolidou MT, Alexopoulos EI, Damani E, Liakos N, Chaidas K, Boultadakis E, Apostolidis T, Gourgoulianis K, Kaditis AG. Absence of blood pressure, metabolic, and inflammatory marker changes after adenotonsillectomy for sleep apnea in Greek children. Pediatr Pulmonol 2008;43:550-560.
19. Tam CS, Wong M, McBain R, Bailey S, Waters KA. Inflammatory measures in children with obstructive sleep apnoea. J Paediatr Child Health 2006;42:277-282.
20. Larkin EK, Rosen CL, Kirchner HL, Storfer-Isser A, Emancipator JL, Johnson NL, Zambito AM, Tracy RP, Jenny NS, Redline S. Variation of C-reactive protein levels in adolescents: association with sleep-disordered breathing and sleep duration. Circulation 2005;111:1978-1984.
21. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 2002;288:1728-1732.
22. Iber C, Ancoli-Israel S, Chesson A, Quan SF, for the American Academy of Sleep Medicine. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, 1st edition. Westchester, IL: American Academy of Sleep Medicine; 2007.
23. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-839.
24. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992;267:3581-3584.
25. Sires UI, Griffin GL, Broekelmann TJ, Mecham RP, Murphy G, Chung AE, Welgus HG, Senior RM. Degradation of entactin by matrix metalloproteinases. Susceptibility to matrilysin and identification of cleavage sites. J Biol Chem 1993;268:2069-2074.
26. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-372.
27. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107: 1579-1585.
28. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503. (Pubitemid 24379627)
29. Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, Ivan E. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 2002;91:852-859.
30. Walther T, Schubert A, Falk V, Binner C, Kanev A, Bleiziffer S, Walther C, Doll N, Autschbach R, Mohr FW. Regression of left ventricular hypertrophy after surgical therapy for aortic stenosis is associated with changes in extracellular matrix gene expression. Circulation 2001;104:I54-I58. (Pubitemid 32884777)
31. Saren P, Welgus HG, Kovanen PT. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 1996;157:4159-4165. (Pubitemid 126449330)
32. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997;82:1313-1316. (Pubitemid 27200394)
33. Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000;86:1259-1265.
34. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990;12:1179-1186.
35. Abe N, Osanai T, Fujiwara T, Kameda K, Matsunaga T, Okumura K. C-reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages: inhibitory effect of fluvastatin. Life Sci 2006;78:1021-1028.
36. Glowinska-Olszewska B, Urban M. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism 2007;56:799-805.
37. Roberts CK, Chen AK, Barnard RJ. Effect of a short-term diet and exercise intervention in youth on atherosclerotic risk factors. Atherosclerosis 2007;191:98-106.
38. Li AM, Au CT, Sung RY, Ho C, Ng PC, Fok TF, Wing YK. Ambulatory blood pressure in children with obstructive sleep apnoea: a community based study. Thorax 2008;63:803-809.
39. Amin RS, Kimball TR, Kalra M, Jeffries JL, Carroll JL, Bean JA, Witt SA, Glascock BJ, Daniels SR. Left ventricular function in children with sleep-disordered breathing. Am J Cardiol 2005;95: 801-804.
40. Kaditis AG, Alexopoulos E, Dalapascha M, Papageorgiou K, Kostadima E, Kaditis DG, Gourgoulianis K, Zakynthinos E. Cardiac systolic function in Greek children with obstructive sleep-disordered breathing. Sleep Med 2009; 11:406-412.
41. Dayyat E, Kheirandish-Gozal L, Gozal D. Childhood obstructive sleep apnea: one or two distinct disease entities? Sleep Med Clin 2007;2:433-444.
42. Gozal D, Lipton AJ, Jones KL. Circulating vascular endothelial growth factor levels in patients with obstructive sleep apnea. Sleep 2002;25:59-65. (Pubitemid 34072660)
43. Tauman R, O'Brien LM, Gozal D. Hypoxemia and obesity modulate plasma C-reactive protein and interleukin-6 levels in sleep-disordered breathing. Sleep Breath 2007;11:77-84.
44. Gozal D, Serpero LD, Sans Capdevila O, Kheirandish-Gozal L. Systemic inflammation in non-obese children with obstructive sleep apnea. Sleep Med 2008;9:254-259. (Pubitemid 351387097)
45. Kaditis AG, Gozal D, Snow AB, Kheirandish-Gozal L, Alexopoulos E, Varlami V, Papathanasiou AA, Capdevila OS, Bhattacharjee R, Kim J, Gourgoulianis K, Zintzaras E. Uric acid excretion in North American and Southeast European children with obstructive sleep apnea. Sleep Med 2009;11:489-493.
46. Kaditis AG, Alexopoulos E, Chaidas K, Ntamagka G, Karathanasi A, Tsilioni I, Kiropoulos TS, Zintzaras E, Gourgoulianis K. Urine concentrations of cysteinyl leukotrienes in children with obstructive sleep-disordered breathing. Chest 2009;135:1496-1501.
47. Khalyfa A, Kaditis A, Boazza M, Sans Capdevila O, Kheirandish- Gozal L, Bhattacharjee R, Snow A, Kim J, Gozal D. C-reactive protein (CRP) gene polymorphisms in US and Greek children with suspected obstructive sleep apnea (OSA). Sleep 2009; A0277.